Skip to main content

Innovations in the Technology Space


Join SLAS as we discuss Innovations in the Technology Space. What new techniques, tools, and approaches to solving problems have been developed as of late?

Our panelists will share their innovations and insights:
Steffen Cosson, Ph.D., Senior Scientist at Cellenion will discuss spheroONE - an automated high throughput spheroid isolation and manipulation technology. 

Sylke Hoehnel, CEO & Co-Founder at SUN Bioscience will share how they are standardizing organoids for high-throughput screenings.

Dean Mulyk, Digital Software Manager at Thermo Fisher Scientific will discuss their automation response to Covid. 

This program is FREE


  • Steffen Cosson, Ph.D., Senior Scientist, Cellenion

    Steffen Cosson is currently a senior scientist at Cellenion. He earned is M.Sc. at the Ecole Polytechnique Fédérale de Lausanne (EPFL, Switzerland) in 2008, being amongst the first graduate class of the Life Science and Technology Faculty, and his PhD in the Institute of Bioengineering from EPFL working under Professor M.P. Lutolf, in 2012. His thesis work involved the development of micro-culture platform at the interface between microtechnology, advanced biomaterials and stem cell biology.

    After completing his PhD, he accepted a post-doctoral position (2013-2018) between the University of Queensland (UQ) and the Commonwealth Science and Industrial Research Organization (CSIRO), working on rapid biomaterial discovery for application in tissue engineering and regenerative medicine, under Professor J.J. Cooper-White.

    In 2019, he joined Cellenion as a senior scientist where he is currently leading the spheroONE project which aims at the development of automated spheroids and organoids isolation, sorting and manipulation technology.

  • Sylke Hoehnel, Ph.D., CEO, SUN bioscience

    One of the hottest innovations in science today, organoids model the behavior of real human organs in the dish. These miniature three-dimensional human tissue cultures are extremely effective at testing new drugs, avoiding some of the pitfalls of traditional drug development methods and paving the way for precision medicine. SUN bioscience is focused on standardizing organoid cultures to render them user-friendly and easy-to-adopt in high-throughput screenings.

    Sylke Hoehnel co-founded SUN bioscience with Nathalie Brandenberg, making it one of the rare women-led companies in Switzerland. Sylke was born and raised in Germany and the UK and graduated from the ETH Zurich and EPF Lausanne. During her PhD she co-authored publications in Nature Methods, Nature Cell Biology and Nature Biomedical Engineering. She has received multiple prestigious awards; She was named to Forbes’ inaugural 30 Under 30 Europe list and is a 2018 Fellow of the Cartier Women’s Initiative.

  • Dean Mulyk, B.Sc., M.Sc., Digital Software Manager, Thermo Fisher Scientific

    Dean manages the Lab Automation Digital Software and Connectivity portfolio within Thermo Fisher Scientific. He is focused on the digital transformation that laboratory automation is currently undergoing. He earned his undergraduate and Master degrees in Biological Sciences from the University of Alberta. In his work with Serotonin and other GPCRs prior to Thermo Fisher Scientific, Dean worked with laboratory robotics which in turn developed his interest in laboratory automation. Dean has held multiple positions both at the bench and managing labs & consulting companies.

spheroONE - an automated high throughput spheroid isolation and manipulation technology by Cellenion
Conventional (2D) monolayer culture fails to recapitulate the complexity of native tissue and organs. Recent advances in three-dimensional (3D) in vitro models, in particular spheroids and organoids, offer unprecedented means to replicate human tissues, organs and diseases in a petri dish. Indeed, tumor spheroids display hallmarks of solid tumor such as multicellular composition, spatial architecture, diffusion barrier, differential gene expression and drug resistance, rendering them the model of choice in anti-tumor drug screenings. To date, preparation of spheroids for high throughput screenings are poised to rely on the random aggregation of a cell suspension in overlay culture labware (ca. non-adherent multi-well plates) which raises concern about sample homogeneity and cellular debris scattering. Moreover, to yield reproducible and predictive assays, pre-selection of spheroids based on their size, morphology and intern organization is critical. Hitherto, there is no tractable automated and high throughput means to isolate and manipulate spheroids. By merging Scienion’s sciDROP NANO® low-volume dispensing in air technology and cellenONE® software, Cellenion has developed the spheroONE, an innovative platform to isolate, inspect and dispense large-particle such as 3D spheroids. Here, we highlight the capabilities of the platform by demonstrating our ability to isolate spheroids with high accuracy (up to 100% single spheroid per well) and sort them according to user-defined characteristics (size and morphology). The preparation of assay-ready plates by isolating and dispensing spheroids prepared in bulk has the potential to significantly accelerate drug screening processes and improve their predictability.

Standardizing organoids for high-throughput screenings by SUN bioscience
Stem-cell-derived organoids are now routinely used for the biological and biomedical
modelling of tissues. However, the complexity, lack of standardization and quality control of stem cell culture in solid extracellular matrices hampers the routine use of the organoids at the industrial scale. We present the fabrication of bioengineered cell culture devices and scalable and automated methods for suspension culture and real-time analysis of thousands of individual organoids of various origin. This talk will cover applications for anticancer drug tumoroid screenings, treatment response screenings for Cystic Fibrosis and large-scale imaged based analyses of the blood-brain barrier (BBB). We demonstrate integration by design for the full automation of organoid work-flows.

Thermo Fisher Scientific Amplitude Solution featuring Thermo Scientific’s Momentum Workflow Software
The global scientific response to the COVID19 pandemic was tremendous.(e.g.,
diagnostics, screening of potential therapeutics and vaccine development research, viral biology, etc). However laboratories performing COVID-19 testing continue to face the combined challenges of rapidly scaling workflows to meet the demands of communities while ensuring the accuracy and reproducibility of results. This led to an
increasing need for automated testing methodologies that not only provide sample to
result tracking, but also increasing productivity and minimizing user intervention to meet
industry needs. provided the opportunity to do more with robotic workflows. One such solution is the Thermo Fisher Scientific Amplitude Solution featuring Thermo Scientific’s Momentum workflow software, a highly automated molecular diagnostic testing solution that can analyze up to 8,000 COVID19 specimens in 24 hours. This is a standardized solution which provides a rapidly deployable and consistent solution for diagnostic labs worldwide In addition to the diagnostic systems which address active and ongoing COVID infection, automated serological assays lab automation systems are needed to detect the presence of antibodies in patent samples. This determines if a patient has been exposed to the virus and their level of immune response. Thermo Scientific Momentum automated ELISA systems have been deployed to provide vaccine researchers with critical information on antibody presence and titre to determine
vaccine efficiency.
This presentation will provide:
•An overview of the Amplitude Solution, along with the critical data tracking and automated data interpretation that is required for diagnostic workflows.
•Details about the simple to use dashboard style interface which enables novice-to automation lab technicians to operate the system with minimal hands-on time and
•Case systems which highlight complete data tracking against and end-to-end workflow for assessing response to a vaccine candidate.

April 27, 2021
Tue 10:00 AM EDT

Duration 1H 0M

Already Registered?